Table 1 |.
Cell cycle regulation/impairment | Mediators | Results | References |
---|---|---|---|
RTECs in AKI-CKD | |||
G1/S transition delay | ↑p53/p21 (and p27) and ↓CDK2/cyclin E activity | Improved RTEC recovery after AKI | 46–48 |
Transient CDK4/6 inhibition | Improved RTEC recovery after AKI | 49, 50 | |
G2/M checkpoint arrest | Cyclin → ↑p53/p21 | SASP, TASCC formation, and fibrosis | 6, 7 |
TGF-β → ↑p21 | Tubular damage, EMT, fibrosis | 60, 61 | |
Endocycling (Pax8+ RTECs) | Not identified | Polyploidy and hypertrophy | 89 |
PKD (ADPKD) | |||
Unchecked cell cycle progression | Loss of PC1 → ↓p53/p21 | RTEC hyperproliferation | 97, 172, 173 |
Loss of PC1 → ↑Cux1, ↑Pax2 |
108, 111, 112 86, 87, 114 |
||
Premature G1/S transition | Loss of PC1 → ↓STAT1 activation → ↓Yp21 | Cell cycle progression and hyperproliferation | 97 |
Loss of PC1 → ↑cyclin A | 98, 99 | ||
Loss of PC2 → ↑Id2 nuclear translocation and gene expression | 100 | ||
Cytokinesis defects | Loss of PC1 | Centrosomal amplification, MC | 131, 141 |
Mitotic slippage/endomitosis, aberrant ploidy | |||
RTECs in HIVAN | |||
G2/M checkpoint arrest | Vpr → DNA damage response (ATM/ATR) | Caspase-mediated cell death | 160, 161, 171 |
Cytokinesis defects | Vpr→ FAT10 | Centrosome amplification, MC | 162–166, 171 |
Vpr → DNA-PK | Mitotic slippage/endomitosis, aberrant ploidy |
ADPKD, autosomal dominant polycystic kidney disease; AKI, acute kidney injury; ATM, Ataxia telangiectasia mutated; ATR, ATM and RAD3-related; CDK, cyclin-dependent kinase; CKD, chronic kidney disease; Cux, Cut-like homeobox; DNA-PK, DNA-dependent protein kinase; EMT, epithelial-to-mesenchymal transition; FAT10, HLA-F–adjacent transcript 10; HIVAN, HIV-associated nephropathy; MC, mitotic catastrophe; Pax, paired box; PC1, polycystin-1; PC2, polycystin-2; PKD, polycystic kidney disease; RTEC, renal tubular epithelial cell; SASP, senescence-associated secretory phenotype; STAT, signal transducers and activators of transcription; TASCC, target of rapamycin–autophagy spatial coupling compartment; TGF-β, transforming growth factor-β; Vpr, Viral Protein R.